NASDAQ:VYGR - Voyager Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.79 -0.13 (-1.46 %)
(As of 01/16/2019 08:07 AM ET)
Previous Close$8.92
Today's Range$8.75 - $9.12
52-Week Range$8.30 - $31.91
Volume173,531 shs
Average Volume331,904 shs
Market Capitalization$290.41 million
P/E Ratio-3.33
Dividend YieldN/A
Beta2.73
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopathies, including Alzheimer's disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreement with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as has collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340

Debt

Current Ratio6.08
Quick Ratio6.08

Price-To-Earnings

Sales & Book Value

Annual Sales$10.14 million
Price / Sales28.23
Price / Cash FlowN/A
Book Value$4.26 per share
Price / Book2.06

Profitability

Net Income$-70,690,000.00
Net Margins-648.40%
Return on Assets-37.31%

Miscellaneous

Employees88
Market Cap$290.41 million
OptionableOptionable

Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) issued its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.15. The firm earned $2.09 million during the quarter, compared to analyst estimates of $3.02 million. Voyager Therapeutics had a negative return on equity of 81.63% and a negative net margin of 648.40%. View Voyager Therapeutics' Earnings History.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Voyager Therapeutics.

What price target have analysts set for VYGR?

8 analysts have issued 12-month price targets for Voyager Therapeutics' stock. Their predictions range from $13.00 to $40.00. On average, they anticipate Voyager Therapeutics' stock price to reach $26.6250 in the next twelve months. This suggests a possible upside of 202.9% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics.

What is the consensus analysts' recommendation for Voyager Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our $21 price target is based on a 13-year DCF analysis leveraged solely to the prospects of VY- AADC in PD, which potentially leaves significant upside if the remainder of the pipeline matures favorably. Our DCF analysis is based on: beta of 1.47, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (1/15/2019)
  • 2. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (11/17/2018)
  • 3. BTIG Research analysts commented, "Before mkt open on Thursday, Voyager released their 1Q18 financial results and update. Management reconfirmed that the first patient in the Phase 2-3 Parkinson’s (PD) studies could be dosed during mid-2018, and further confirmed that posterior delivery will be the preferred approach. The decision to use posterior delivery was based upon improved safety, surgical time, and coverage of the putamen – with first data from the posterior study being presented later in 2Q18. The posterior study dataset will focus on patients with 6-months of follow-up, which will be a small group of patients, as the 8 th patient in the posterior study was recently dosed. We reiterate our Buy rating and $32 PT as we remain positive on the PD effort." (5/13/2018)

Has Voyager Therapeutics been receiving favorable news coverage?

Media stories about VYGR stock have trended positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Voyager Therapeutics earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the company's share price in the near term.

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,334,487 shares, a decrease of 31.3% from the December 14th total of 1,941,857 shares. Based on an average trading volume of 484,745 shares, the days-to-cover ratio is presently 2.8 days. Currently, 5.5% of the shares of the stock are sold short. View Voyager Therapeutics' Current Options Chain.

Who are some of Voyager Therapeutics' key competitors?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:
  • Mr. Matthew P. Ottmer, Chief Operating Officer (Age 47)
  • Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 67)
  • Mr. G. Andre Turenne, CEO, Pres & Director
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $8.79.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $290.41 million and generates $10.14 million in revenue each year. The company earns $-70,690,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Voyager Therapeutics employs 88 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel